What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in ...

Regeneron Pharmaceuticals is seeing revenue growth in key products that is now offsetting declining revenue in its previous ...

Over the past six months, Regeneron’s stock price fell to $587.01. Shareholders have lost 11.7% of their capital, which is ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory ...

The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals, Inc.’s (NASDAQ: REGN) Evkeeza ...

In the preceding three months, 15 analysts have released ratings for Regeneron Pharmaceuticals REGN, presenting a wide array of perspectives from bullish to bearish. The table below provides a concise ...

Regeneron remains a 'Strong Buy' amid investor concerns and strong drug performances. Read here for more financial analysis ...

While the company is making efforts to diversify its revenue base and develop its oncology franchise, Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ ...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock ...

Chautauqua Capital Management, a division of Baird Asset Management, is a boutique investment firm that released its second ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options become available today, for the September 5th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...